In the absence of an international convention on the naming of biological medicines, the Canadian regulator is looking at various options before it decides on a formal approach to distinguish between biologic drugs that have the same non-proprietary name. It wants to adopt an approach that allows accurate identification, is compatible with existing drug information systems and databases, and is easy to implement.
Health Canada is inviting stakeholder feedback on the best possible approach to naming of biologic drugs, including biosimilars, to enable their accurate identification throughout the medication-use process, including prescribing, dispensing, administration and documentation.
With the entry of biosimilars into the Canadian market, the regulator believes the time is right for it to decide...